{ "items": [ "\n\n
\n \n\n \n \n \n \n Alzheimer's\n \n \n \n \n Child development\n \n \n \n \n Community Mental Health Services\n \n \n \n \n Neuroscience\n \n \n \n \n Parenting\n \n \n \n \n Prevention\n \n \n \n \n Psychosis\n \n \n \n \n Schizophrenia\n \n \n\n \n\n\n
\n \n \n \nWe conduct independent ethics research and we deliver ethical guidance for a range of scientific and clinical studies in the Oxford Department of Psychiatry and Neuroscience. We also work with a variety of international institutions and researchers. Our core research interests involve young people, mental health and neuroscience innovations in a global context.
\n \n\n \n \n\n \n\n \n \n \n \n Anxiety\n \n \n \n \n Behavioural models\n \n \n \n \n Brain function\n \n \n \n \n Brain imaging\n \n \n \n \n Decision-making\n \n \n \n \n Depression\n \n \n \n \n Neuroscience\n \n \n\n \n\n\n
\n \n \n \nUsing computer models of behaviour, we aim to better understand anxiety and depression, and to guide the development of novel treatments.
\n \n\n \n \n\n \n\n \n \n \n \n Behaviour\n \n \n \n \n Brain\n \n \n \n \n Brain imaging\n \n \n \n \n Cognitive\n \n \n \n \n Cognitive models\n \n \n \n \n Decision-making\n \n \n \n \n Dopamine\n \n \n \n \n Functional imaging\n \n \n \n \n Genetics\n \n \n \n \n Magnetic Resonance Imaging (MRI)\n \n \n \n \n Magnetoencephalography (MEG)\n \n \n \n \n Mood\n \n \n \n \n Neuroimaging\n \n \n \n \n Neuroscience\n \n \n \n \n Pharmacology\n \n \n \n \n Risk factors\n \n \n \n \n Schizophrenia\n \n \n \n \n Stress\n \n \n\n \n\n\n
\n \n \n \nOur research aims to understand how individual genes contribute to the complex brain functions that are impaired in people with psychiatric disorders. By understanding these links we hope to improve treatments for these disorders.
\n \n\n \n \n\n \n\n \n \n \n \n Alzheimer's\n \n \n \n \n Case registers\n \n \n \n \n Clinical trial\n \n \n \n \n Dementia\n \n \n \n \n Dopamine\n \n \n \n \n Neuroscience\n \n \n \n \n Parkinson's\n \n \n\n \n\n\n
\n \n \n \nThe Translational Neuroscience and Dementia Research Group undertake translational research ranging from mechanisms to drug development, and from discovery to qualification of molecular and imaging biomarkers in both Alzheimer\u2019s disease and Parkinson\u2019s disease and in related dementia disorders. The group, led by Professor Noel Buckley, comprises molecular and cellular biology scientists, computational biologists and informaticians working with molecular, clinical and imaging datasets. \r\nWe have three main areas of activity, all aiming towards secondary prevention of dementia. By understanding disease mechanisms we seek potential therapeutics; through discovery of biomarkers we hope to enable preventative trials, and with informatics we utilise large biological and clinical datasets in the support of translational neuroscience.
\n \n\n \n \n\n \n\n \n \n \n \n Alzheimer's\n \n \n \n \n Brain\n \n \n \n \n Brain function\n \n \n \n \n Brain imaging\n \n \n \n \n Clinical trial\n \n \n \n \n Cognitive models\n \n \n \n \n Cohorts\n \n \n \n \n Dementia\n \n \n \n \n Empirical\n \n \n \n \n Functional imaging\n \n \n \n \n Genetics\n \n \n \n \n Magnetic Resonance Imaging (MRI)\n \n \n \n \n Medical imaging\n \n \n \n \n Neuroimaging\n \n \n \n \n Neurology\n \n \n \n \n Neuroscience\n \n \n \n \n Parkinson's\n \n \n \n \n Risk factors\n \n \n \n \n Whitehall Study\n \n \n\n \n\n\n
\n \n \n \nNeuroimaging provides a window into the living brain, and is an increasingly vital experimental medicine tool for neuro-psychiatric disease. With a particular focus on early and pre-clinical disease, we explore how the brain changes before symptoms take hold.
\n \n\n \n \n\n \n\n \n \n \n \n Depression\n \n \n \n \n Economic recession\n \n \n \n \n Epidemiology\n \n \n \n \n Mental illness\n \n \n \n \n Prevention\n \n \n \n \n Risk factors\n \n \n \n \n Self-harm\n \n \n \n \n Suicide\n \n \n\n \n\n\n
\n \n \n \n\n \n \nOur mission is to promote the healthy mental and physical development of children and their families around the globe, irrespective of their life circumstances. Our work focuses on development in the face of adversity, including perinatal mental health difficulties, life threatening conditions such as HIV and cancer, and situations of violence, war and poverty. We are working on how to improve access to mental health communication, supports and services, including in schools, online and using digital interventions.
\n \n\n \n \nOur research includes projects in the epidemiology of mental illness and violent crime, violence risk assessment, prison health, pharmacoepidemiology studies, forensic services, and suicide and self-harm in prisoners and offenders. More recent work has focused on suicide prevention, particularly in people with severe mental illness.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical trial\n \n \n \n \n Dissemination\n \n \n \n \n Distribution\n \n \n \n \n Epidemiology\n \n \n \n \n Evidence based treatment\n \n \n \n \n Prevention\n \n \n \n \n Psychological treatment development and evaluation\n \n \n\n \n\n\n
\n \n \n \nCREDO was established in 1981. The main focus of its research is on the treatment of eating disorders. More recently, it has also developed methods to facilitate the dissemination of effective psychological interventions. It is in the process of creating a digital treatment for eating disorders (CBTe).
\n \n\n \n \nOHBA is a research facility providing state-of-the-art techniques to measure or stimulate activity in the living human brain. Groups at OHBA investigate brain function in healthy volunteers, and in individuals affected by psychiatric and neurological conditions.
\n \n\n \n \nThe Oxford Psychological Medicine Research group aims to improve the lives of people with medical-psychiatric multimorbidity through high quality research.\r\n \r\nWe research the psychological and psychiatric problems of patients with medical conditions, develop innovative treatments to address these, and test the treatments in rigorous randomised trials.
\n \n\n \n \nWe are interested in the molecular and neural basis of schizophrenia and bipolar disorder, and how the risk genes for these disorders operate. We use a range of platforms, methods, and collaborations, to carry out this work.
\n \n\n \n \n\n \n\n \n \n \n \n Anxiety\n \n \n \n \n Behaviour\n \n \n \n \n Behavioural models\n \n \n \n \n Bipolar\n \n \n \n \n Brain\n \n \n \n \n Brain function\n \n \n \n \n Brain imaging\n \n \n \n \n Cognitive\n \n \n \n \n Cognitive models\n \n \n \n \n Depression\n \n \n \n \n Experimental\n \n \n \n \n Functional imaging\n \n \n \n \n Mental illness\n \n \n \n \n Neuroimaging\n \n \n \n \n Neuroscience\n \n \n \n \n Psychology\n \n \n \n \n Treatment\n \n \n\n \n\n\n
\n \n \n \nWe explore how the brain processes emotional information and how this is influenced by brain chemicals and medicines. This helps us to understand disorders such as depression and anxiety and to understand and contribute to the development of drug and psychological treatments.
\n \n\n \n \n\n \n\n \n \n \n \n Brain imaging\n \n \n \n \n Depression\n \n \n \n \n Drug treatment\n \n \n \n \n Evidence Based Medicine\n \n \n \n \n Magnetic Resonance Imaging (MRI)\n \n \n \n \n Mental illness\n \n \n \n \n Neuroimaging\n \n \n \n \n Pharmacology\n \n \n\n \n\n\n
\n \n \n \nOur research aims to understand how psychotropic drugs work at molecular level. By exploring this through clinical research in patients we contribute to the development of new evidence-based pharmacological treatments for severe mental illness.
\n \n\n \n \n\n \n\n \n \n \n \n Alzheimer's\n \n \n \n \n Brain imaging\n \n \n \n \n Depression\n \n \n \n \n Whitehall Study\n \n \n\n \n\n\n
\n \n \n \nWhy do some people suffer from depression and memory loss as they age, whereas others stay well for the whole of their lives? We examine the effect of genes and life history on ageing using neuropsychology and neuro-imaging techniques as part of large scale epidemiological and experimental medicine studies.
\n \n\n \n \nWe are dedicated to testing and developing new ways of improving treatments for psychiatric disorders, and maintaining brain health during aging. A significant proportion of people suffering from disturbances of mood and memory, do not respond to the available medication, and so there is an urgency to supplement or provide an alternative to current therapies.
\n \n\n \n \n\n \n\n \n \n \n \n Behaviour\n \n \n \n \n Child development\n \n \n \n \n Clinical psychology\n \n \n \n \n Clinical trial\n \n \n \n \n Cognitive models\n \n \n \n \n Depression\n \n \n \n \n Evidence based treatment\n \n \n \n \n Mindfulness\n \n \n \n \n Mood\n \n \n \n \n Self-harm\n \n \n\n \n\n\n
\n \n \n \nOur work focuses on preventing depression, promoting mental health and resourcing people to meet the challenges of the next 50 years.
\n \n\n \n \n\n \n\n \n \n \n \n Behavioural models\n \n \n \n \n Brain\n \n \n \n \n Brain function\n \n \n \n \n Brain imaging\n \n \n \n \n Clinical psychology\n \n \n \n \n Clinical trial\n \n \n \n \n Cognitive\n \n \n \n \n Cognitive models\n \n \n \n \n Dependence\n \n \n \n \n Experimental\n \n \n \n \n Functional imaging\n \n \n \n \n Information processing\n \n \n \n \n Magnetic Resonance Imaging (MRI)\n \n \n \n \n Magnetoencephalography (MEG)\n \n \n \n \n Mindfulness\n \n \n \n \n Mood\n \n \n \n \n Neuroimaging\n \n \n \n \n Neuroscience\n \n \n \n \n Nutrition\n \n \n \n \n Psychological treatment development and evaluation\n \n \n \n \n Psychopathology\n \n \n \n \n Research-based\n \n \n \n \n Treatment\n \n \n \n \n Treatment trials\n \n \n\n \n\n\n
\n \n \n \nWe work to understand the cognitive, biological, emotional and somatic processes underpinning the severe eating disorder Anorexia Nervosa in particular, and Eating Disorders in general. Our trans-disciplinary research, involving clinicians and neuroscientists, aims to translate research findings into novel treatment strategies.
\n \n\n \n \n